The firm will use the funds to support clinical trials of its ATR inhibitor alnodesertib and its pol theta inhibitor ART6043.

The company plans to use the proceeds to test its TCR-T cell therapy in patients with MAGE-A4-positive solid tumors.

The recommendation is based on the Phase II/III DEVOTE study testing the higher dose in treatment-naïve patients and those already on the low dose.